| __timestamp | Bausch Health Companies Inc. | GSK plc |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 7323000000 |
| Thursday, January 1, 2015 | 2645000000 | 8853000000 |
| Friday, January 1, 2016 | 2611000000 | 9290000000 |
| Sunday, January 1, 2017 | 2548000000 | 10342000000 |
| Monday, January 1, 2018 | 2351000000 | 10241000000 |
| Tuesday, January 1, 2019 | 2350000000 | 11863000000 |
| Wednesday, January 1, 2020 | 2249000000 | 11704000000 |
| Friday, January 1, 2021 | 2394000000 | 11603000000 |
| Saturday, January 1, 2022 | 2364000000 | 9554000000 |
| Sunday, January 1, 2023 | 2559000000 | 8565000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis delves into the cost of revenue trends for GSK plc and Bausch Health Companies Inc. from 2014 to 2023. Over this period, GSK consistently maintained a higher cost of revenue, averaging around 10 billion annually, compared to Bausch Health's 2.4 billion. However, the gap narrowed significantly in recent years, with GSK's cost of revenue decreasing by approximately 17% from its peak in 2019, while Bausch Health's figures remained relatively stable. This shift highlights GSK's strategic efforts to optimize operational efficiency. As the industry faces increasing pressure to reduce costs, these insights provide a valuable perspective on how leading companies are adapting to maintain competitiveness. Understanding these trends is crucial for investors and stakeholders aiming to make informed decisions in the pharmaceutical sector.
Cost of Revenue Comparison: AstraZeneca PLC vs GSK plc
Comparing Cost of Revenue Efficiency: GSK plc vs Dr. Reddy's Laboratories Limited
Comparing Cost of Revenue Efficiency: GSK plc vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc.
Incyte Corporation vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Bausch Health Companies Inc.
Cost Insights: Breaking Down Catalent, Inc. and Bausch Health Companies Inc.'s Expenses
Bausch Health Companies Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bausch Health Companies Inc. and Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Bausch Health Companies Inc. and Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.